Tranylcypromine/trifluoperazine
Combination drug
From Wikipedia, the free encyclopedia
Tranylcypromine/trifluoperazine (brand names Parstelin, Parmodalin, Jatrosom N, Stelapar) is a combination formulation of the monoamine oxidase inhibitor antidepressant drug tranylcypromine and the typical antipsychotic drug trifluoperazine that has been used in the treatment of major depressive disorder.[1][2][3] It contains 10 mg tranylcypromine and 1 mg trifluoperazine.[3][4] The drug has been in clinical use since at least 1961.[3]
Trade namesParstelin, Parmodalin, Jatrosom N, Stelapar
| Combination of | |
|---|---|
| Tranylcypromine | Monoamine oxidase inhibitor |
| Trifluoperazine | Typical antipsychotic |
| Clinical data | |
| Trade names | Parstelin, Parmodalin, Jatrosom N, Stelapar |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
It may come to assume a certain place in the treatment of borderline personality disorder.[5]
